Other reports have also shown a role for PAX5 in oncogenic or pro-aggressive features in astrocytoma [96,97], lung cancer [94], cervical carcinoma [98], bladder cancer [95], oral carcinoma [99], neuroblastoma [92], and medulloblastoma [93]. Here, PAX5 is linked to urinary bladder cancer.